Are we ready for clinical proteomics?

The integration of proteomic technologies into clinical practice indeed holds significant promise for revolutionizing disease diagnosis, prognosis, and treatment. By delving into the intricate world of proteins and their modifications, researchers aim to unravel the complexities underlying various diseases. The advanced proteomic technologies also offer unprecedented opportunities to investigate the interplay between genomic, transcriptomic, and proteomic alterations. By employing these technologies to investigate tumors, we have gained invaluable insights into cancer biology, particularly pertaining to protein modifications such as glycosylation. 张会，中国籍，毕业于北京大学，获得学士和硕士学位，并在宾夕法尼亚大学获得博士学位。她曾在新英格兰生物实验室、细胞信号技术、系统生物学研究所和约翰霍普金斯大学工作。目前，张会博士是约翰霍普金斯大学病理学、肿瘤学、泌尿学、化学和生物分子工程教授。她是生物标志物发现和翻译中心质谱核心设施和蛋白质组学研究的主任。她的研究重点是了解蛋白质和蛋白质修饰的功能，特别是蛋白质糖基化在生物学和人类疾病中的作用。